On 16 July 2020, Race was pleased to report results of the investigator led Phase II trial of bisantrene for relapsed or refractory Acute Myleoid Leukaemia. This post summarises the highlights and provides access to key resources related to the data read out.
Analysis of Phase II trial of bisantrene for relapsed or refractory Acute Myleoid Leukaemia (R/R AML) showed an objective clinical response in 40% of patients
Of the 10 patients treated, one patient achieved a complete remission and three patients achieved partial remission, a response rate comparable to historical bisantrene trials
Bisantrene had marked activity in 4 out of 4 patients with the difficult to treat extramedullary (outside of the bone marrow) form of AML
Bisantrene was well tolerated with no unexpected serious toxicities
R/R AML represents a significant therapeutic challenge with no clearly established standard of care
Summary of resources:
Investors are invited to access the following resources related to the data read out:
Impressive 40% clinical response rate in Phase II bisantrene AML trial: view announcement
Race Oncology is a specialty pharmaceutical company whose business model is to pursue later stage drug assets, principally in the cancer field. Our first important asset is a chemotherapy drug called Bisantrene.